You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 51 - 60 of 204654 results
  1. Video observed therapy to enhance flexibility and reduce in-person visits for patients treated with methadone in a multi-site opioid treatment program

    SBC: EMOCHA MOBILE HEALTH INC.            Topic: NIDA

    PROJECT SUMMARY The COVID-19 pandemic intersecting with the opioid epidemic led to dramatic shifts in the delivery of care for opioid use disorders (OUD). Historically, methadone has been provided as directly-observed therapy (DOT) at opioid treatment programs (OTPs). This model of care delivery has been a barrier to accessing care due to imposed travel burden and disruption to work and family res ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. CardioWatch: An Omics-Based Prediction Assay for Cardiac Late Effects ofAcute Radiation

    SBC: NELSON SCIENTIFIC LABS LLC            Topic: NIAID

    Concerted efforts have led to the development of medical countermeasures against acute radiation toxicity in victims of a radiological accident or nuclear terrorism, thereby significantly increasing the chance of survival if such a radiological event were to occur today. However, survivors of acute radiation toxicities may develop delayed injuries that become clinically apparent months to years af ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Development of Coccidioides Cytokine Release Assay

    SBC: MIRAVISTA DIAGNOSTICS LLC            Topic: NIAID

    Coccidioidomycosis (CM) is an endemic mycosis caused by the fungi Coccidioides immitis and Coccidioides posadasii, which is native to arid regions of North and South America. It is estimated that up to 350,000 infections occur annually in the U.S. Additionally, up to a third of community acquired pneumonia cases in these areas are thought to be a result of CM. Morbidity associated with CM is subst ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Bench-top Reader and Aptamer-based Assay for Rapid, High-sensitivity Drug/Opiate Detection

    SBC: BASE PAIR BIOTECHNOLOGIES INC            Topic: NIBIB

    Project Summary/Abstract The United States is experiencing an epidemic of unprecedented scope with heroin use resurging and a troubling pervasive increase in abuse of prescription opioids such as fentanyl, fentanyl derivatives, methadone, oxycodone and hydrocodone. More than 6 out of 10 drug overdoses are now opioid-related, resulting in ~90 deaths/day and a more than $75B/year economic impact. Ad ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant

    SBC: Marker Therapeutics, Inc.            Topic: NCI

    ABSTRACT This Phase II application will advance MT-401, a novel multi-tumor associated antigen (mTAA)-specific T cell product for the treatment of acute myeloid leukemia (AML) and other cancers. In the USA, ~3,500 AML patients receive hematopoietic stem cell therapy (HSCT) every year, but overall survival remains lt30%, with an estimated median survival of lt1 year. Although AML is sensitive to im ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a Novel Oral Antibiotic for the Treatment of Drug Resistant Gonorrhea

    SBC: AIMMAX THERAPEUTICS INC            Topic: NIAID

    PROJECT SUMMARY / ABSTRACT The CDC has identified Neisseria gonorrhoeae as a pathogen of the highest threat level (“Urgent Threat”) to the US public health. Currently there is only a single recommended agent remaining on the CDC treatment guidelines, an intramuscular injection of the extended spectrum cephalosporin, ceftriaxone. However, in the past decade, reports of resistance to ceftriaxone ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. XVIR-110 an ultra-long-acting INSTI for HIV pre-exposure prophylaxis in IND-enabling studies

    SBC: EXAVIR THERAPEUTICS INC.            Topic: NIAID

    PROJECT SUMMARY While there are now successful treatment regimens and prevention strategies for people living with HIV/AIDS, the HIV pandemic remains a public health crisis in the United States and worldwide, with nearly 40,000 new infections each year in the US alone. To prevent the spread of HIV in vulnerable populations, the US Preventive Services Task Force has recommended HIV pre-exposure pro ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. AGR2-superantigen vaccine conjugate for the treatment of pancreaticductal adenocarcinoma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: 101

    Project Summary/Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest forms of cancer. Poor survival rates are largelydue to the late stage at which PDAC is diagnosed and a lack of effective targeted therapies. While the field ofimmunotherapy has significantly increased overall survival in some malignancies, they have not translated toPDAC. The long-term goal of this research pr ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites

    SBC: EMMUNE INC            Topic: R

    We are developing vaccine antigens for SARS-CoV-2 that focus the antibody response onto neutralizing epitopes in the receptor binding domain (RBD) of the viral Spike (S) protein. Booster antigens derived from variants of SARS-CoV-2 would especially benefit from being limited to the RBD, due to the preponderance of conserved but non-neutralizing epitopes in the full-length S protein. However, RBD-o ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Zeno Power Systems Strategic Financing Increase (STRATFI) Proposal

    SBC: ZENO POWER SYSTEMS, INC.            Topic: AF192D001

    At Zeno, we’re developing an next-generation radioisotope power system (RPS) that operates by converting the heat from decaying radioisotopes directly into electricity – providing always-on, resilient power in the W-kW range for years at a time. NASA and the U.S. Department of Defense have historically used RPSs, but the cost or weight of these systems limited their broader usability. Zeno's ...

    SBIR Phase II 2022 Department of DefenseAir Force
US Flag An Official Website of the United States Government